https://doi.org/10.55788/6a8ddf10
Short-acting Ī²2-agonists provide quick asthma symptom relief but fail to address underlying inflammation. Combining short-acting Ī²2-agonist albuterol (180 Ī¼g) and corticosteroid budesonide (160 Ī¼g) in a single, as-needed, rescue inhaler for asthma could provide rapid bronchodilation while treating airway inflammation. The phase 3, double-blind, randomised, event-driven MANDALA trial (NCT03769090) looked at patients with uncontrolled moderate-to-severe asthma and asked whether this fixed-dose rescue inhaler could lower the risk for severe asthma exacerbations compared with albuterol monotherapy used as a rescue inhaler. Prof. Alberto Papi (University of Ferrara, Italy) presented the results, which were simultaneously published inĀ the New England Journal of Medicine [1,2].
MANDALA enrolled patients with moderate-to-severe asthma of >3 years old who had had Ā³1 severe exacerbation in the prior 12 months. Despite allowing children, only 183 of 3,132 randomised participants were paediatric patients; the mean age of the intention-to-treat population was 49 years. Participants were allocated to 1 of 3 arms: an arm receiving the combination with a high-dose of budesonide (albuterol 180 Āµg/budesonide 160 Āµg), a lower-dose arm (albuterol 180 Āµg/budesonide 80 Āµg), or albuterol 180 Āµg alone. Study medication was administered through blinded, pressurised metered-dose inhalers. All patients continued receiving maintenance inhaled corticosteroids either with or without other medications for their asthma.
The primary endpoint was time to first severe asthma exacerbation, which reported a 27% reduction among participants assigned a fixed-dose combination of the higher dose combination compared with albuterol 180 Āµg alone (HR 0.73; 95% CI 0.61ā0.88; P<0.001). Similarly, a 17% reduction was observed with the lower-dose combination arm (HR 0.83; 95% CI 0.7ā0.99; P=0.041), but the data did suggest a dose-response. In an additional intention-to-treat analysis, risk was reduced by 26% with the higher-dose combination (HR 0.74; 95% CI 0.62ā0.89; P=0.001) and 16% with the lower-dose combination (HR 0.84; 95% CI 0.71ā1.0; P=0.052).
With regard to safety, the incidence of any adverse event was nearly identical across all 3 groups, with 46.2% in the higher-dose combination group, 47.1% in the lower-dose combination group, and 46.4% in the albuterol-only group. Similarly, serious adverse events occurred in 5.2%, 3.8%, and 4.5%, respectively. Adverse events were consistent with the known safety profiles of the individual components; the most common adverse events were nasopharyngitis, headache, and upper respiratory tract infection.
In another session, Dr Bradley Chipps (Capital Allergy & Respiratory Disease Center, CA, USA) presented the results of the phase 3 DENALI trial (NCT03847896) [3]. DENALI was a randomised, double-blind, placebo-controlled, multicentre, parallel-group trial. Similar to MANDALA, it evaluated the efficacy and safety of albuterol/budesonide in a single inhaler but compared it with albuterol and budesonide monotherapy in patients with mild-to-moderate asthma (excluding children aged 4ā11 years). Participants (n=1,001) were randomised to 5 treatment groups in a 1:1:1:1:1 ratio: albuterol/budesonide 180/160 Ī¼g 4 times daily, albuterol/budesonide 180/80 Ī¼g 4 times daily, albuterol alone 180 Ī¼g 4 times daily, budesonide 160 Āµg 4 times daily, or placebo 4 times daily. The trial started with 2ā4 weeks of baseline screening, 12 weeks of treatment, and included an additional 2 weeks of follow-up.
The 2 primary efficacy endpoints were designed to gauge the effect of the individual components: (1) the change from baseline in forced expiratory volume in one second (FEV1) area under the curve 0ā6 hours over 12 weeks of albuterol/budesonide treatment compared with budesonide monotherapy to assess the effect of albuterol, and (2) change from baseline in trough FEV1 at weekĀ 12 of albuterol/budesonide compared with albuterol monotherapy to assess the effect of budesonide. Secondary endpoints included the time to onset and duration of response, number of patients who achieved a clinically meaningful benefit in asthma control at week 12, and trough FEV1 at week 1.
DENALI met its dual primary endpoints. The researchers reported a statistically significant improvement for combined albuterol/budesonide in FEV1 at week 12 compared with budesonide (least-squares mean [LSM] difference 80.7 mL; 95% CI 28.4ā132.9; P=0.003), as well as versus albuterol (LSM difference 132.8 mL; 95% CI 63.6ā201.9 and 120.8 mL; 95% CI 51.5ā190.1, for 80 and 160 Ī¼g budesonide, respectively; both P<0.001). The onset of action and duration of effect were similar on day 1. The safety profiles for both albuterol/budesonide doses were similar to those of each of the individual components.
āGiven the efficacy of adding budesonide to albuterol as a rescue medication and the duration of the treatment, we believe that this is going to be a potential change in the paradigm of the use of rescue medication,ā Prof. Papi concluded.
- Papi A,Ā et al.Ā Efficacy and safety of as-needed albuterol/budesonide versus as-needed albuterol in adults, adolescents and children aged ā„4 years with moderate-to-severe asthma: Results of the MANDALA study. Session B12, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
- Papi A,Ā et al.Ā N Engl J MedĀ 2022; May 15. DOI: 10.1056/NEJMoa2203163.
- Chipps BE, et al. Efficacy and safety of albuterol/budesonide (PT027) in mild-to-moderate asthma: Results of the DENALI study. Session B93, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« ACOUSTICS data sounds good for adolescent asthma exacerbations Next Article
Paediatric long COVID lacks definitions »
« ACOUSTICS data sounds good for adolescent asthma exacerbations Next Article
Paediatric long COVID lacks definitions »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
October 30, 2022
Sustained hypoxaemia predicts unprovoked VTE in OSA
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com